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LETTER
Silencing of hsa-miR-124 by EVI1 in
cell lines and patients with acute
myeloid leukemia
We read with great interest the work published by Dickstein
et al. (1) showing that induced EVI1 expression in a murine
model silences miR-124 expression by DNA methylation. The
EVI1 gene codes for a transcription factor implicated in the
development and progression of high-risk acute myeloid leuke-
mia (AML) (2, 3). We quantify the expression of 250 micro-
RNAs (miRNAs; TaqManHuman miRNA assay set) in 15
myeloid cell lines. Statistical analysis comparing cell lines with
and without EVI1 protein identiﬁed miRNAs differentially ex-
pressed (B > 0). Among them, cell lines with EVI1 protein had
no expression of hsa-miR-124, whereas most cell lines with no
EVI1 had high hsa-miR-124 expression (Table 1). Interestingly,
MEG-01 cells, with EVI1 overexpression and no protein, ex-
pressed low levels of hsa-miR-124 (Fig. 1 and Table 1). We ﬁrst
considered whether EVI1 was a target of hsa-miR-124. Tran-
siently, transfection of pre–hsa-miR-124 in HEL and KU-812 cell
lines, both with EVI1 protein and no hsa-miR-124 expression,
showed a dramatic increase of hsa-miR-124; however, no
changes in EVI1 expression either at the mRNA or protein level
were detected. These results indicate that hsa-miR-124 does not
regulate EVI1 expression. The results of Dickstein et al. (1)
prompted us to examine whether DNA methylation could be
responsible for the low expression of hsa-miR-124 in cell lines
with EVI1 protein (1). We analyzed the methylation status of
hsa-miR-124-1 by methylation-speciﬁc PCR as previously de-
scribed (4). All of the cell lines analyzed that had low expression
of hsa-miR-124 had the promoter methylated: four had EVI1,
and three had no protein. Conversely, the two cell lines with high
expression of hsa-miR-124 had no methylation and no EVI1
(Table 1). These results strongly support the hypothesis that
EVI1 silences hsa-miR-124 expression by DNA methylation (1),
although they would also indicate that, in some cases, the ex-
pression of hsa-miR-124 might be regulated by other mecha-
nisms. To check the clinical importance of these results, we
analyzed 42 AML patients, 19 of which had EVI1 overexpression
(Table 1). Consistent with our results in cells lines, expression of
EVI1 in patients was associated with decreased expression of
hsa-miR-124 (P = 0.036), supporting that EVI1 could play a
role in the transcriptional regulation of hsa-miR-124 (Fig. 1).
Nevertheless, as in cell lines, some cases with low hsa-miR-124
expression had no EVI1 overexpression.
Further studies are needed to fully clarify the role of hsa-miR-
124 silencing in EVI1-positive AML. As shown in other malig-
nancies, cyclin-dependent kinase 6 (CDK6) could be a target of
hsa-miR-124 in AML. In the HEL cell line (hsa-miR-124-1–
methylated and CDK6-expressed), we found that CDK4/6 in-
hibition by PD-0332991 induced dephosphorylation of retino-
blastoma (Rb), with no changes in the protein levels of Rb or
CDK6, and inhibited cell growth. These results may provide al-
ternatives for future AML treatment. In conclusion, our results
support the ﬁndings of Dickstein et al. (1), suggesting that
a common mechanism for hsa-miR-124 down-regulation in he-
matological malignancies is the methylation of the promoter
region of this gene and that EVI1 has a role in the transcriptional
regulation of hsa-miR-124 expression.
Iria Va´zqueza, Miren Maicasa,b, Nerea Marcoteguia, Ana Conchilloa,
Elisabet Guruceagac, Jose´ Roman-Gomezd, Marı´a J. Calasanzb,
Xabier Agirrea, Felipe Prospera, Marı´a D. Oderoa,b,1
aDivision of Oncology, Center for Applied Medical Research (CIMA),
University of Navarra, 31008 Pamplona, Spain; bDepartment of
Genetics, University of Navarra, 31008 Pamplona, Spain; cUnit of
Proteomics, Genomics and Bioinformatics, Center for Applied
Medical Research (CIMA), University of Navarra, 31008 Pamplona,
Spain; dDepartment of Hematology, Reina Soﬁa Hospital, 14004
Cordoba, Spain
ACKNOWLEDGMENTS. This work was supported by Ministerio Ciencia
Innovación (PI081687), Instituto de Salud Carlos III del Ministerio de Ciencia e
Innovación–Red Temática de Investigación Cooperativa en Cáncer (RD06/
0020/0078-RD06/0020/0111), and Union temporal de empresas (UTE)
proyecto Centro de Investigación Médica Aplicada (CIMA).
1. Dickstein J, et al. (2010) Methylation and silencing of miRNA-124 by EVI1 and self-
renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome.
Proc Natl Acad Sci USA 107:9783–9788.
2. Nucifora G, Laricchia-Robbio L, Senyuk V (2006) EVI1 and hematopoietic disorders:
History and perspectives. Gene 368:1–11.
3. Wieser R (2007) The oncogene and developmental regulator EVI1: Expression, bio-
chemical properties, and biological functions. Gene 396:346–357.
4. Agirre X, et al. (2009) Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-
124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic
leukemia. Cancer Res 69:4443–4453.
Author contributions: I.V. and M.D.O. designed research; I.V., M.M., N.M., J.R.-G., and A.C.
performed research; I.V., M.M., E.G., M.J.C., and X.A. analyzed data; and I.V., X.A., F.P.,
and M.D.O. wrote the paper.
The authors declare no conﬂict of interest.
1To whom correspondence should be addressed. E-mail: modero@unav.es.
www.pnas.org/cgi/doi/10.1073/pnas.1011540107 PNAS Early Edition | 1 of 2
Fig. 1. Diagram showing the expression of hsa-miR-124 in 15 myeloid cell lines and 42 samples of patients with AML. Data represents the mean ± SE.
Table 1. Quantiﬁcation of the expression of hsa-miR-124 and methylation status of the hsa-miR-124-1 promoter region in 15 human
myeloid cell lines
Cell line Diagnosis hsa-miR-124 (2-dct)
hsa-miR-124–1
(methylation status) Evi1 protein
Overexpression (qRT-PCR)
EVI1-1A EVI1-1B EVI1-1C EVI1-1D EVI1-3L MDS1EVI1
MV4-11 AML-M5 4.2575 UM No No No No No No No
NOMO-1 AML-M5 3.3870 UM No No No No No No No
MOLM-13 AML-M5 3.1602 nd No No No No No No No
OCI-AML2 AML-M4 5.2780 nd No No No No No No No
MEG-01 CML-BP 0.1022 nd No No Yes No No No No
KG-1 AML-M6 0.0337 M No No No No No No No
Kasumi-1 AML-M2 0.0000 M No No No No No No No
HL-60 AML-M2 0.0000 M No No No No No No No
MUTZ-3 AML-M4 0.0398 M Yes Yes Yes Yes Yes No No
KU-812 CML-BP 0.0009 nd Yes No Yes No No No No
TF-1 AML-M6 0.0001 M Yes Yes Yes Yes Yes No No
HEL AML-M6 0.0001 M Yes Yes Yes Yes Yes No No
K562 CML-BP 0.0001 nd Yes Yes Yes No No No Yes
F-36P AML-M6 0.0001 M Yes Yes Yes Yes Yes No No
KYO-1 CML-BP 0.0001 nd Yes No Yes Yes No No No
CML-BP, chronic myeloid leukemia blast phase; M, methylated; nd, no data; UM, unmethylated.
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